Oncology

Showing 15 posts of 310 posts found.

Rethinking oncology trial endpoints with generalised pairwise comparisons

November 4, 2025
Research and Development EMA, FDA, Oncology, One2Treat, clinical trials, generalised pairwise comparisons, net treatment benefit, oncology

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival (OS) and progression-free survival (PFS) …

Five Facts about Breast Cancer

October 2, 2025
Medical Communications Breast Cancer Awareness Month, Five Facts, Oncology, breast cancer

1 There are striking inequities in breast cancer burden regarding the Human Development Index (HDI), the United Nationโ€™s measure of …

Combination treatments: Takedaโ€™s Implementation Framework and the broader landscape

September 23, 2025
Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …

Er-Kim to distribute CNX Therapeuticsโ€™ oncology drugs across Europe and Turkey

August 29, 2025
Logistics & Distribution, Manufacturing and Production, Mergers and Acquisitions CNX Therapeutics, Corporate, Er-Kim, Oncology, central nervous system disorders, critical care

Turkish pharma company, Er-Kim, has signed a distribution agreement with CNX Therapeutics to expand access to a portfolio of oncology …

EMA grants orphan drug designation for Rocaโ€™s treatment of radiation maculopathy

August 28, 2025
Medical Communications, Research and Development European Medicines Agency (EMA), Oncology, Opthalmology, Roca Therapeutics, maculopathy

The European Medicines Agency (EMA) has granted Orphan Drug Designation to Roca Therapeutics for its lead candidate RCT002, marking the …

Neogap Therapeutics appoints Jonas Mattson to its board of directors

August 26, 2025
Research and Development Corporate, Immunology, Neogap Therapeutics, Oncology, board of directors

Swedish biotech, Neogap Therapeutics, has appointed Jonas Mattson, an authority in cell therapy, to its board of directors. His appointment …

HUTCHMED completes enrolment in phase 3 trial for lung cancer

August 21, 2025
Research and Development HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination …

Lung cancer cells

Graphene-based biosensor to support new lung cancer screening test

August 18, 2025
Business Services, Research and Development Ease Healthcare, Hawkeye Bio, HydroGraph, Oncology, lung cancer

HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and Ease Healthcare to support the …

money-2180330_960_720

Anocca secures ยฃ32m to advance pancreatic cancer trial

August 18, 2025
Research and Development Anocca, Oncology, Pancreatic cancer, research funding

Swedish biopharma Anocca has raised approximately ยฃ32m (SEK 440m) to support the early-stage clinical development of VIDAR-1, its lead TCR-T …

ARTBIO expands board and establishes technical advisory board

August 11, 2025
Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals

ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …

drug-trials

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

August 7, 2025
Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …

blood-1813410_960_720

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

August 6, 2025
Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofiโ€™s investigational monoclonal antibody developed for …

Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer

August 1, 2025
Medical Communications, Research and Development Oncology, Ryvu Therapeutics, colorectal cancer

Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific Reports. The study reveals a …

The Gateway to Local Adoption Series

Latest content